Exscalate4COV’s League members are industrial and scientific entities, not formally part of the Consortium, but that contribute materials and knowledge to the project through our DrugBox or by other means.

CFEL Center for Free-Electron Laser Science

CFEL donated CoV-2 Mpro Protease for assay development. They also performed a high-throughput crystallization libraries screening to find Mpro ligands and publish novel protease complex crystals.

MMV Medicines for Malaria Ventures

MMV donated 2 large libraries (The Pandemic Response Box and The Pathogen Box) of drug-like molecules (800 compounds) active against infective diseases, both viral and bacterial-based for testing.


ESTEVE Pharmaceuticals is contributing to the fight against the COVID-19 pandemic from different perspectives:
1) Guarantee of supply of essential medicines included in our portfolio.
2) Collaboration in national and international investigations against COVID-19, including the Exscalate4COV project. We sent proprietary and non-proprietary compounds from our chemical library to be assayed for their potential antiviral activity against SARS-CoV-2 through this initiative.
3) Donations of protection material (Personal Protective Equipment) and laboratory equipment to increase the diagnostic throughput and achieve massive screening of the population. 4) Social responsibility. ESTEVE is sending fresh food to Hospitals and food donations to Food Banks to be distributed to the most vulnerable families and people.

University of Basel Biozentrum

SIB's Computational Structural Biology (CSB) group which runs SWISS-MODEL is hosted at the Biozentrum of the University of Basel

University of Basel Innovation Office

The Innovation Office is reinforcing dissemination and communication activity facilitating contacts with potential partners from the scientific and industrial community.

University of Basel Department of Pharmaceutical Sciences

Department of Pharmaceutical Sciences at University of Basel provided a list of selected compounds potentially active against coronavirus to be tested in vitro.


D-Wave Provides Free Quantum Cloud Access for Global Response to COVID-19


“Taking part in the EXSCALATE4CoV project was a straightforward decision for Pierre Fabre. We have always been very strong believers in joining forces for the benefit of patients and the global fight against the corona virus makes it even more necessary.”
Jean Luc LOWINSKI CEO Pierre Fabre Medical Care


A journey of a thousand miles begins with a single step: Greenpharma, happy to partecipate to this journey against Covid-19, has sent molecules for testing.

University of Sheffield - Sheffield Institute for Translational Neuroscience - SITraN

University of Sheffield has sent molecules for testing


Relying on physical experimentation alone is not economically sustainable in today’s rapidly evolving COVID-19 environment. Scientists need a deeper understanding of both how and why potential antiviral therapies and vaccines will perform against COVID-19, and they need it today.
As an active supporter of the scientific community that is collaborating today on COVID-19 solutions, BIOVIA, Dassault Systèmes develops BIOVIA Discovery Studio. This world-class life sciences modeling and simulation environment brings together over 30 years of peer-reviewed research and world-class in silico technique.
It provides researchers with a complete toolset for use from target identification through lead optimization, including tools for biologics design and analysis, classical simulations, structure- and fragment-based design, virtual ligand screening, as well as ADME and toxicity prediction.
As part of Dassault Systèmes’ corporate social responsibility, BIOVIA Dassault Systèmes is pleased to offer academic research groups involved in SARS-CoV-2 related studies a no-charge, six-month license to BIOVIA Discovery Studio to assist them in the search for rapid, safe and effective therapeutic drug candidates against the SARS-CoV-2 virus.
This offer will run through June 30, 2020.


Alfasigma provided four proprietary molecules approved for the treatment of malaria, infections or inflammation for investigating their possible repurposing as anti-viral drugs.


Eni has made its supercomputing infrastructure and its molecular modeling skills available for Coronavirus research to the consortium freely, offering its contribution with its tools and resources of excellence in the fight against this global emergency. Eni has already started the activity with Cineca, and is providing the consortium with its technical skills and its HPC5 supercomputing system, the world's most powerful supercomputer for industrial use. Its hybrid architecture makes the algorithms for molecular simulation particularly efficient.

Institute of Food Science Research (CIAL-CSIC)

Foodomics laboratory from CSIC, Spain, contributed sending some compounds for testing against SARS-CoV-2.

Nanome Inc.

The American company Nanome Inc. is supporting us making their Virtual Reality technology available to serve the consortium partners. Nanome is currently used as one of the tools to help combat the virus by enabling scientists to gain insights into the molecular mechanics of the virus.

CECAM Centre Européen de Calcul Atomique et Moleculaire

CECAM, headquartered in the Campus of Ecole polytechnique fédérale de Lausanne (EPFL), promotes fundamental research on advanced computational methods and their application to important problems in frontier areas of science and technology.
24 Institutions from 14 European countries, including Ministries, National Research Councils, Research and High Performance Computing Centres, Universities, fund CECAM and concur in defining its strategy and activities. CECAM is supporting the dissemination activity through the organization of webinars and scientific workshops.

Institut Cochin

Institut Cochin, affiliated to INSERM, CNRS and the Université de Paris, is a renowned French research institut located in the heart of Hospital Cochin in Paris downtown, dedicated to the investigation of human pathologies in the domains of endocrinology, metabolism, cancer, infection, immunology and others. Our researchers are fully engaged in the fight against COVID-19 and are actively collaborating with the European Consortium EXSCALATE4COV by suppling a diversity of compounds to be tested in the search of a treatment for this disease.

Sofia University “St. Kl. Ohridski”, Faculty of Physics

Sofia University “St. Kl. Ohridski” is the oldest and most respected university in Bulgaria. The Biophysics and Biomodeling Group at the Physics Faculty, in collaboration with researchers from several institutes of the Bulgarian Academy of Sciences, works on the unblocking of the immune response in infected by SARS-Cov-2 cells. The group will collaborate with the European Consortium EXSCALATE4COV by providing simulation results and potential compounds to be tested for their immunity restoration potential.

Università degli Studi della Tuscia

The Department for Innovation in Biological, Agro-food and Forest systems (DIBAF) of Tuscia University (Italy), together with the University of Florida (USA) and University of Monastir/University of Manouba (Tunisia), are actively collaborating with the European Consortium EXSCALATE4COV by providing the MD trajectories produced in the framework of the awarded PRACE project “Molecular Dynamics investigation of the interaction between ACE2 and the spike glycoprotein of SARS-CoV-2”, currently running on Marconi100 @CINECA.

ESTECO (Trieste, Italy)

ESTECO is offering its expertise in numerical optimization, post-processing analysis and simulation data management to support the COVID19-related research. ESTECO technology, tools and practical support will be used by POLIMI to maximize the throughput of the “in-silico” screening of molecules.

IT4Innovation (Ostrava, Czech Republic)

IT4Innovations National Supercomputing Center at VSB – Technical University of Ostrava is supporting through cooperation with POLIMI the E4C consortium in terms of tools, and computing resources in the fight against this global emergency.


GPCRmd, led by the GPCR Drug Discovery group at the Hospital del Mar Medical Research Institute - Pompeu Fabra University (Barcelona), is a web platform specialized in the dissemination of molecular dynamics simulations for G protein-coupled receptors.
GPCRmd contributes to the fight against the COVID-19 pandemic by applying their expertise to develop a web platform for the dissemination of molecular dynamics simulations for SARS-CoV-2 related proteins. For that, it provides a collection of online tools to easily visualize, analyze and share such data.


SAS is supporting Excalate4CoV project with its analytics solutions and expertise.

Thanks to innovative technology, artificial intelligence and analytics, SAS will help research groups getting insight from the data to identify the most promising model.


c/o Dompé Farmaceutici
Via Pietro Castellino, 111
80131 Napoli, Italy